Humacyte/$HUMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Humacyte
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
Ticker
$HUMA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
219
ISIN
US44486Q1031
Website
Humacyte Metrics
BasicAdvanced
$366M
-
-$0.65
1.64
-
Price and volume
Market cap
$366M
Beta
1.64
52-week high
$9.79
52-week low
$1.15
Average daily volume
4.7M
Financial strength
Current ratio
3.68
Quick ratio
3.162
Long term debt to equity
215.898
Total debt to equity
228.927
Interest coverage (TTM)
-10.61%
Profitability
EBITDA (TTM)
-103.773
Gross margin (TTM)
-15,934.82%
Net profit margin (TTM)
-15,022.44%
Operating margin (TTM)
-21,470.79%
Management effectiveness
Return on assets (TTM)
-42.82%
Return on equity (TTM)
-249.75%
Valuation
Price to revenue (TTM)
567.444
Price to book
10.16
Price to tangible book (TTM)
10.16
Price to free cash flow (TTM)
-2.91
Free cash flow yield (TTM)
-34.36%
Free cash flow per share (TTM)
-81.09%
Growth
Earnings per share change (TTM)
-35.93%
3-year revenue growth (CAGR)
-27.22%
3-year earnings per share growth (CAGR)
16.92%
What the Analysts think about Humacyte
Analyst ratings (Buy, Hold, Sell) for Humacyte stock.
Bulls say / Bears say
Humacyte's SYMVESS™ received full FDA approval for treating extremity vascular trauma in December 2024, marking a significant milestone in vascular surgery. (TipRanks)
The commercial launch of SYMVESS™ is progressing well, with 34 hospitals initiating the Value Analysis Committee approval process and initial shipments made to Level 1 trauma centers. (TipRanks)
Insiders have shown confidence in Humacyte by purchasing approximately $803,000 worth of stock over the past year, indicating a positive outlook on the company's future. (Simply Wall St)
Humacyte reported no revenue for 2024, continuing a trend from 2023, and its net loss increased to $148.7 million, raising concerns about financial sustainability. (TipRanks)
The company announced a public offering of 25 million shares at $2 each, leading to a 23.5% premarket drop in share price, reflecting potential dilution concerns among investors. (TradingView News)
Humacyte responded to recent media coverage with an SEC filing, addressing unspecified attacks, which may indicate underlying issues affecting investor confidence. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Humacyte Financial Performance
Revenues and expenses
Humacyte Earnings Performance
Company profitability
Humacyte News
AllArticlesVideos
Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
GlobeNewsWire·2 weeks ago
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
GlobeNewsWire·3 weeks ago
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Humacyte stock?
Humacyte (HUMA) has a market cap of $366M as of June 20, 2025.
What is the P/E ratio for Humacyte stock?
The price to earnings (P/E) ratio for Humacyte (HUMA) stock is 0 as of June 20, 2025.
Does Humacyte stock pay dividends?
No, Humacyte (HUMA) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Humacyte dividend payment date?
Humacyte (HUMA) stock does not pay dividends to its shareholders.
What is the beta indicator for Humacyte?
Humacyte (HUMA) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.